In patients with relapsed myeloma starting carfilzomib therapy, baseline elevation with brain natriuretic peptide (BNP) or N-terminal proBNP (NT-ProBNP) conferred an 11-fold risk for cardiovascular adverse events on treatment [7]. The gene discussed is NPPB; the disease is plasma cell myeloma.